Screener
Beam Therapeutics BEAM Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of contingent consideration liabilities | 514 | (27) |
| Interest and other income (expense), net | 9,867 | 9,864 |
| Total other income (expense) | 12,897 | 10,956 |
| Net loss | $(94,318) | $(108,330) |
| Unrealized gain (loss) on marketable securities | (2,181) | (519) |
| Comprehensive loss | $(96,499) | $(108,849) |
| Net loss per common share, basic and diluted | $(0.91) | $(1.23) |
| Weighted-average common shares outstanding, basic and diluted | 103,262,001 | 87,975,311 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's net income?
- Beam Therapeutics (BEAM) reported net income of -$94.32M in Q1 2026.
- How has Beam Therapeutics's net income changed year-over-year?
- Beam Therapeutics's net income increased by 12.9% year-over-year, from -$108.33M to -$94.32M.
- What is the long-term trend for Beam Therapeutics's net income?
- Over 2 years (2021 to 2024), Beam Therapeutics's net income has grown at a 0.8% compound annual growth rate (CAGR), from -$370.64M to -$376.74M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Beam Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude